Siemens Healthineers : Q2 2021-22 due 4 May – Similar performance to Q1 expected
>Q2 2021-22 to be a solid quarter - We forecast revenues of € 5.264bn, an increase of c. 33% y-o-y. This includes Varian (consolidated as of Q3 2020-21 only) and an estimated 5% y-o-y FX tailwind with comparable revenue growth estimated at 9.0% y-o-y. Rapid antigen test sales (€ 380m estimated for Q2 vs € 190m in Q2 last year) will have contributed an estimated 4.8% y-o-y to that, so the underlying performance would look solid to us. Our revenue forecast is only sligh...Siemens Healthineers AG is a Germany-based company that supplies technology to the healthcare industry. The Company offers a wide range of products and services in the fields of diagnostic and therapeutic imaging, laboratory and point of care diagnostics, and molecular medicine. It provides medical technology and software solutions, as well as clinical consulting services. Additionally, the Company is developing its digital health and enterprise services trough expanding precision medicine, transforming care delivery, improving patient experience, and digitalizing healthcare to enable healthcare providers to increase value. Siemens AG is a majority shareholder of the Company. The Company is active worldwide.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.